Undertreatment with anti-osteoporotic drugs after hospitalization for fracture

被引:0
|
作者
Martien J. M. Panneman
Paul Lips
Shuvayu S. Sen
Ron M. C. Herings
机构
[1] PHARMO Institute,Department of Endocrinology
[2] Academic Hospital Vrije Universiteit Amsterdam,Whitehouse Station
[3] Merck & Co. Inc.,Department of Pharmaco
[4] Utrecht University,epidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences
来源
Osteoporosis International | 2004年 / 15卷
关键词
Anti-osteoporotic drugs; Fracture; Osteoporosis; Undertreatment;
D O I
暂无
中图分类号
学科分类号
摘要
This study assessed the proportion of patients treated with anti-osteoporotic drugs during the 1-year period after hospitalization for a fracture, and the influence of a guideline in the period 1998–2000 on the likelihood of receiving treatment for osteoporosis after a fracture. Patients were assessed retrospectively for anti-osteoporotic drug use during a 1-year period following hospitalization for non-traumatic fracture. The PHARMO system, a population-based database (n=865,000) containing drug and hospitalization data of community-dwelling inhabitants of defined areas in the Netherlands, was used. The study population comprised 1654 patients age 50 years and over who were admitted to hospital for a fracture resulting from a fall during the period 1998–2000. The treatment rate of newly treated patients and the change in treatment rate throughout the period 1998–2000 were the outcome measures. The majority of these patients were women (73%), and had femur fractures (51%). In total, 247 out of 1654 patients (15%) were prescribed anti-osteoporotic drugs within 1 year after discharge from the hospital. Of these 247 patients, 86 were newly treated, mainly with bisphosphonates in the year after discharge following the fracture, yielding a new treatment rate of 5%. The likelihood of receiving treatment for osteoporosis following fracture did not change with the calendar year of fracture (OR 0.95; 95% CI: 0.68–1.30). The result of this study shows that despite the introduction of an osteoporosis treatment guideline in 1999 recommending treatment for fracture patients, most of the time, fracture patients are not being treated for osteoporosis. Thus, to a large extent, osteoporosis remains under-treated.
引用
收藏
页码:120 / 124
页数:4
相关论文
共 50 条
  • [1] Undertreatment with anti-osteoporotic drugs after hospitalization for fracture
    Panneman, MJM
    Lips, P
    Sen, SS
    Herings, RMC
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (02) : 120 - 124
  • [2] Use of anti-osteoporotic drugs in central Norway after a forearm fracture
    Hoff, Mari
    Skurtveit, Svetlana
    Meyer, Haakon E.
    Langhammer, Arnulf
    Sogaard, Anne Johanne
    Syversen, Unni
    Abrahamsen, Bo
    Schei, Berit
    ARCHIVES OF OSTEOPOROSIS, 2015, 10 (01)
  • [3] Use of anti-osteoporotic drugs in central Norway after a forearm fracture
    Mari Hoff
    Svetlana Skurtveit
    Haakon E. Meyer
    Arnulf Langhammer
    Anne Johanne Søgaard
    Unni Syversen
    Bo Abrahamsen
    Berit Schei
    Archives of Osteoporosis, 2015, 10
  • [4] The biology of fracture healing in osteoporosis and in the presence of anti-osteoporotic drugs
    Hak, David J.
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2018, 49 (08): : 1461 - 1465
  • [5] Guidelines for the development of anti-osteoporotic drugs
    Avouac, B
    THERAPIE, 2003, 58 (05): : 421 - 424
  • [6] Assessment of previous fracture and anti-osteoporotic medication prescription in hip fracture patients
    Cathal J. McCarthy
    Michael A. Kelly
    Paddy J. Kenny
    Irish Journal of Medical Science (1971 -), 2022, 191 : 247 - 252
  • [7] Assessment of previous fracture and anti-osteoporotic medication prescription in hip fracture patients
    McCarthy, Cathal J.
    Kelly, Michael A.
    Kenny, Paddy J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (01) : 247 - 252
  • [8] Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
    Aypak, Cenk
    Bircan, Mustafa A.
    Ozdemir, Ayse
    RAMBAM MAIMONIDES MEDICAL JOURNAL, 2022, 13 (03):
  • [9] Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
    Fozi, Nur Farhana Mohd
    Mazlan, Mazliadiyana
    Shuid, Ahmad Nazrun
    Mohamed, Isa Naina
    CURRENT DRUG TARGETS, 2013, 14 (14) : 1659 - 1666
  • [10] Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database
    Iolascon, Giovanni
    Gimigliano, Francesca
    Moretti, Antimo
    Riccio, Ilaria
    Di Gennaro, Massimo
    Illario, Maddalena
    Monetti, Valeria Marina
    Orlando, Valentina
    Menditto, Enrica
    CLINICAL CASES IN MINERAL AND BONE METABOLISM, 2016, 13 (02) : 127 - 130